Yıl: 2021 Cilt: 36 Sayı: 2 Sayfa Aralığı: 219 - 226 Metin Dili: İngilizce DOI: 10.46497/ArchRheumatol.2021.8229 İndeks Tarihi: 29-09-2021

Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis

Öz:
Objectives: This study aims to evaluate the effects of ocrelizumab (OCZ) on familial Mediterranean fever (FMF) attacks in multiple sclerosis (MS) patients with FMF (MS+FMF patients).Patients and methods: This retrospective observational study included 11 patients (2 males, 9 females; mean age 46.6±9.2; range, 22 to 55 years) with MS+FMF hospitalized between January 2016 and July 2019. Demographic, clinical, and laboratory parameters and patient reported outcomes were analyzed in patients treated with OCZ for 18 months.Results: Combining OCZ with colchicine in MS+FMF patients significantly reduced the frequency of FMF attacks (p=0.003) and the frequency of joint attacks (p=0.002). Consistent with the clinical improvement, the maximum serum C-reactive protein levels were significantly decreased after combination therapy compared to before combination therapy (p=0.003). MS+FMF patients reported that FMF disease activity improved after OCZ therapy (Visual Analog Scale [VAS] 74±9.6 vs. VAS 46.5±8.1 mm, p=0.003).Conclusion: Ocrelizumab therapy led to a prominent decrease in the frequency of FMF attacks, alleviated functional impairment, and improved quality of life in MS+FMF patients.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Akman-Demir G, Gul A, Gurol E, Ozdogan H, Bahar S, Oge AE, et al. Inflammatory/ demyelinating central nervous system involvement in familial Mediterranean fever (FMF): coincidence or association? J Neurol 2006;253:928-34.
  • 2. Unal A, Dursun A, Emre U, Tascilar NF, Ankarali H. Evaluation of common mutations in the Mediterranean fever gene in Multiple Sclerosis patients: is it a susceptibility gene? J Neurol Sci 2010;294:38-42.
  • 3. Alpayci M, Bozan N, Erdem S, Gunes M, Erden M. The possible underlying pathophysiological mechanisms for development of multiple sclerosis in familial Mediterranean fever. Med Hypotheses 2012;78:717-20.
  • 4. El Hasbani G, Jawad A, Uthman I. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF). Orphanet J Rare Dis 2019;14:224.
  • 5. Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol 2019;266:1182-93.
  • 6. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162-73.
  • 7. Pras M. Familial Mediterranean fever: from the clinical syndrome to the cloning of the pyrin gene. Scand J Rheumatol 1998;27:92-7.
  • 8. Mor A, Shinar Y, Zaks N, Langevitz P, Chetrit A, Shtrasburg S, et al. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum 2005;35:57-64.
  • 9. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 1983;17:45-56.
  • 10. Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A, et al. FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis 2014;73:897-901.
  • 11. Kalyoncu U, Eker A, Oguz KK, Kurne A, Kalan I, Topcuoglu AM, et al. Familial Mediterranean fever and central nervous system involvement: a case series. Medicine (Baltimore) 2010;89:75-84.
  • 12. Balcı-Peynircio¤lu B, Kaya-Akça Ü, Arıcı ZS, Avcı E, Akkaya-Ulum ZY, Karada¤ Ö, et al. Comorbidities in familial Mediterranean fever: analysis of 2000 genetically confirmed patients. Rheumatology (Oxford) 2020;59:1372-80.
  • 13. Kümpfel T, Gerdes LA, Wacker T, Blaschek A, Havla J, Krumbholz M, et al. Familial Mediterranean fever-associated mutation pyrin E148Q as a potential risk factor for multiple sclerosis. Mult Scler 2012;18:1229-38.
  • 14. Yahalom G, Kivity S, Lidar M, Vaknin-Dembinsky A, Karussis D, Flechter S, et al. Familial Mediterranean fever (FMF) and multiple sclerosis: an association study in one of the world's largest FMF cohorts. Eur J Neurol 2011;18:1146-50.
  • 15. Ozaras N, Akman-Demir G, Ustek D, Eraksoy M, Abaci N, Gul A. Does FMF gene exist in multiple sclerosis and contribute to the progression? Neurology Asia 2014;19:235-6.
  • 16. Shinar Y, Livneh A, Villa Y, Pinhasov A, Zeitoun I, Kogan A, et al. Common mutations in the familial Mediterranean fever gene associate with rapid progression to disability in non-Ashkenazi Jewish multiple sclerosis patients. Genes Immun 2003;4:197-203.
  • 17. Kaunzner UW, Gauthier SA. MRI in the assessment and monitoring of multiple sclerosis: an update on best practice. Ther Adv Neurol Disord 2017;10:247-61.
  • 18. Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med 1974;291:934-7.
  • 19. French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997;17:25-31.
  • 20. Saito M, Nishikomori R, Kambe N. [Familial Mediterranean fever: MEFV gene mutations and treatment]. Nihon Rinsho Meneki Gakkai Kaishi 2007;30:78-85.
  • 21. Alghamdi M. Familial Mediterranean fever, review of the literature. Clin Rheumatol 2017;36:1707-13.
  • 22. Wu B, Xu T, Li Y, Yin X. Interventions for reducing inflammation in familial Mediterranean fever. Cochrane Database Syst Rev 2015;3:CD010893.
  • 23. Tunca M, Akar S, Soytürk M, Kirkali G, Resmi H, Akhunlar H, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebocontrolled trial. Clin Exp Rheumatol 2004;22(4 Suppl 34):S37-40.
  • 24. Ozdogan H, Ugurlu S. Canakinumab for the treatment of familial Mediterranean fever. Expert Rev Clin Immunol 2017;13:393-404.
  • 25. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for colchicineresistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 2012;157:533-41.
  • 26. Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, et al. Anakinra for colchicine-resistant familial mediterranean fever: A randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2017;69:854-62.
  • 27. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar- Or A, Comi G, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017;376:209-20.
  • 28. Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 1993;14:196-204.
  • 29. Schuh E, Berer K, Mulazzani M, Feil K, Meinl I, Lahm H, et al. Features of Human CD3+CD20+ T Cells. J Immunol 2016;197:1111-7.
APA Demir C, BALGETİR F, ETHEMOĞLU ö, Aksoy D, DEMİRDÖĞEN F, Koca S, Yetkin M, Tasci I (2021). Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis. , 219 - 226. 10.46497/ArchRheumatol.2021.8229
Chicago Demir Caner Feyzi,BALGETİR FERHAT,ETHEMOĞLU özlem,Aksoy Durdane,DEMİRDÖĞEN FİLİZ,Koca Suleyman Serdar,Yetkin Mehmet Fatih,Tasci Irem Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis. (2021): 219 - 226. 10.46497/ArchRheumatol.2021.8229
MLA Demir Caner Feyzi,BALGETİR FERHAT,ETHEMOĞLU özlem,Aksoy Durdane,DEMİRDÖĞEN FİLİZ,Koca Suleyman Serdar,Yetkin Mehmet Fatih,Tasci Irem Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis. , 2021, ss.219 - 226. 10.46497/ArchRheumatol.2021.8229
AMA Demir C,BALGETİR F,ETHEMOĞLU ö,Aksoy D,DEMİRDÖĞEN F,Koca S,Yetkin M,Tasci I Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis. . 2021; 219 - 226. 10.46497/ArchRheumatol.2021.8229
Vancouver Demir C,BALGETİR F,ETHEMOĞLU ö,Aksoy D,DEMİRDÖĞEN F,Koca S,Yetkin M,Tasci I Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis. . 2021; 219 - 226. 10.46497/ArchRheumatol.2021.8229
IEEE Demir C,BALGETİR F,ETHEMOĞLU ö,Aksoy D,DEMİRDÖĞEN F,Koca S,Yetkin M,Tasci I "Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis." , ss.219 - 226, 2021. 10.46497/ArchRheumatol.2021.8229
ISNAD Demir, Caner Feyzi vd. "Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis". (2021), 219-226. https://doi.org/10.46497/ArchRheumatol.2021.8229
APA Demir C, BALGETİR F, ETHEMOĞLU ö, Aksoy D, DEMİRDÖĞEN F, Koca S, Yetkin M, Tasci I (2021). Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis. Archives of Rheumatology, 36(2), 219 - 226. 10.46497/ArchRheumatol.2021.8229
Chicago Demir Caner Feyzi,BALGETİR FERHAT,ETHEMOĞLU özlem,Aksoy Durdane,DEMİRDÖĞEN FİLİZ,Koca Suleyman Serdar,Yetkin Mehmet Fatih,Tasci Irem Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis. Archives of Rheumatology 36, no.2 (2021): 219 - 226. 10.46497/ArchRheumatol.2021.8229
MLA Demir Caner Feyzi,BALGETİR FERHAT,ETHEMOĞLU özlem,Aksoy Durdane,DEMİRDÖĞEN FİLİZ,Koca Suleyman Serdar,Yetkin Mehmet Fatih,Tasci Irem Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis. Archives of Rheumatology, vol.36, no.2, 2021, ss.219 - 226. 10.46497/ArchRheumatol.2021.8229
AMA Demir C,BALGETİR F,ETHEMOĞLU ö,Aksoy D,DEMİRDÖĞEN F,Koca S,Yetkin M,Tasci I Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis. Archives of Rheumatology. 2021; 36(2): 219 - 226. 10.46497/ArchRheumatol.2021.8229
Vancouver Demir C,BALGETİR F,ETHEMOĞLU ö,Aksoy D,DEMİRDÖĞEN F,Koca S,Yetkin M,Tasci I Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis. Archives of Rheumatology. 2021; 36(2): 219 - 226. 10.46497/ArchRheumatol.2021.8229
IEEE Demir C,BALGETİR F,ETHEMOĞLU ö,Aksoy D,DEMİRDÖĞEN F,Koca S,Yetkin M,Tasci I "Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis." Archives of Rheumatology, 36, ss.219 - 226, 2021. 10.46497/ArchRheumatol.2021.8229
ISNAD Demir, Caner Feyzi vd. "Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis". Archives of Rheumatology 36/2 (2021), 219-226. https://doi.org/10.46497/ArchRheumatol.2021.8229